Skip to main content

Table 2 Anakinra efficacy by disease

From: Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey

Disease

No. of patients

Clinical response (available data)

Median treatment duration (days) (IQR)

Associated * treatment

CCS

DMARDs

Still treated

Associated treatment reduction

None

Partial

Total

     

AOSD

35

3 (8.6%)

12 (34.3%)

19 (54.3%)

461 (1164)

28/34 (82.4%)

24/28 (85.7%)

26/28 (92.9%)

15/35 (42.9%)

25/34 (73.5%)

Gout

28

0

6 (21.4%)

22 (78.6%)

7 (96.5)

20/27 (74.1%)

7/20 (35%)

0

3/24 (12.5%)

22/24 (91.7%)

sJIA

26

3 (11.5%)

12 (46.2%)

11 (42.3%)

502 (1154)

22/23 (95.7%)

20/22 (90.1%)

9/22 (40.9%)

10/26 (38.5%)

22/25 (88%)

CAPS

21

0

6 (28.6%)

15 (72.4%)

1059 (1235)

7/18 (38.9%)

3/8

2/9

10/21 (47.6%)

11/13

FMF

13

1 (7.6%)

6 (46.2%)

6 (46.2%)

390 (814.5)

10/12 (83.3%)

4/12 (33.3%)

2/12 (16.7%)

7/13 (53.8)

6/9 (66.7%)

MKD

10

0

7 (70.0%)

3 (30.0%)

266 (448)

3/4

1/4

0/4

3/10

3/3

SAPHO

9

4 (44.4%)

4 (44.4%)

1 (11.1%)

86 (337)

4/8

1/4

1/4

2/9

3/6

Schnitzler’s syndrome

7

1 (16.7%)

0

5 (83.3%)

479 (1227)

4 (/5)

2/4

1/4

4/7

5/6

Spondyloarthritis

5

4

1

0

30 (10–91)

3/5

1/5

0/5

0/5

3/5

Vasculitis

4

0

2

1

424 (94–916)

3/3

3/3

1/3

2/4

3/3

Chondro

calcinosis

4

1

2

1

52 (6–227)

2/4

1/4

1/4

2/4

2/4

GPP

3

0

0

3

56 (6–129)

2/3

1/3

0/3

1/3

2/3

Polychondritis

3

0

2

1

395 (110–1961)

3/3

3/3

3/3

1/3

2/3

TRAPS

3

0

2

1

215 (29–225)

3/3

3/3

0/3

2/3

2/3

NAPS12

2

0

2

0

797

2/2

0/2

0/2

0/2

0/2

  1. CCS: corticosteroids. AOSD: adult onset Still’s disease, sJIA: systemic juvenile idiopathic arthritis, CAPS: cryopyrin associated periodic syndrome, FMF: familial Mediterranean fever, MKD: mevalonate kinase deficiency, Vasculitis: giant cell arteritis (2) and polyarteritis nodosa (2), GPP: generalized pustular psoriasis, TRAPS: tumor necrosis factor receptor-associated periodic syndrome, NAPS 12: NLRP12-associated periodic syndrome, IQR: interquartile range.
  2. *Several patients received colchicine with anakinra: 13 Gout, 8 FMF, 2 NAPS 12, 1 AOSD and 1 sJIA.